알림

알림 Pro 차트

Ovid Therapeutics Inc. (OVID)

NasdaqCM: OVID · 실시간 가격 · USD

2.83

+0.03 (1.07%)

종가 기준: Aug 14, 2026, 3:59 PM

2.78

-1.77%

애프터마켓: 7:34 PM

1.07% (1D)

매수호가	2.04
시가총액	528.19M
매출 (ttm)	1.58M
순이익 (ttm)	-34.48M
베타	0.23
EPS (ttm)	-0.21
P/E (ttm)	n/a
선행 P/E	-7.18
P/B (ttm)	2.49
P/S (ttm)	333.66
Earnings Date	Nov 11, 2026

매도호가	3.52
거래량	1,240,941
평균 거래량 (20일)	2,261,453
시가	2.80
전일 종가	2.80
일중 범위	2.75 - 2.87
52주 범위	0.84 - 3.10
애널리스트	Strong Buy
목표주가	5 (76.68%)
배당	n/a
배당락일	n/a

OVID 소개

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activa...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 5, 2017

직원 수 23

상장 거래소 NasdaqCM

티커 OVID

웹사이트 https://www.ovidrx.com

전체 기업 정보

재무 실적

2025년 Ovid Therapeutics의 매출은 7.25M로, 전년 566K 대비 1,181.27% 증가했습니다. 순이익은 -17.41M로, -34.12% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 9명의 투자의견을 종합하면 OVID 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 5로, 최근 주가 대비 76.68% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Ovid Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.

EPS -0.08 예상치 상회 0.02, 및 -33.33% 전년 대비 감소.

다음 실적 발표

Ovid Therapeutics Inc.의 실적 발표 예정일은 Nov 11, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Zacks

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1주 전 · Zacks

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1개월 전 · Insider Monkey

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin No...

2 페이지 중 1

Ovid Therapeutics Inc. (OVID)